Tackling remaining safety concerns as the era of commercial genome editing-based therapeutics arrives
On- and off-target editing analysis—which tools/models should we use?
What is the current state-of-the-art in the area of multiplex editing analysis?
Analysis of the pros and cons of genome editing and gene writing platforms as next-generation approaches enter the clinic
To what extent is promising preclinical data being borne out in humans?
What are the key opportunities to utilize CRISPR knockout and how to capitalize?
Gene editing delivery: the benefits and challenges in applying viral and non-viral platforms
What improvements can recent innovations in the enzymes area deliver?
What are the pros and cons of next-generation Cas technologies in application?
Predicting future developments in gene editing and its application
What can we expect in the way of further regulatory guidance for the field? What are some of the key areas of convergence/divergence to look out for?
Assessing the epigenome editing opportunity: what is possible currently in the realm of epigenetic modulation, and what might the future hold in the context of both combinatorial and synergistic therapeutic approaches?

Reviewing the major clinical development stories from the past 12 months and their likely repercussions for the cell and gene therapy field
Profiling key enabling technology innovation trends and advances for the years to come

CELL AND GENE THERAPY INSIGHTS

Cell and Gene Therapy Spotlights 2024